Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices

Eman Hassan Elsayed Hassan; Riham Fadl Moftah

doi:doi:10.11648/j.ajim.20160401.12

| Peer-Reviewed

Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices

Eman Hassan Elsayed Hassan, Riham Fadl Moftah

Published in American Journal of Internal Medicine (Volume 4, Issue 1)

Received: 16 January 2016 Accepted: 26 January 2016 Published: 16 February 2016

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. Autoimmune diseases such as rheumatoid arthritis (RA), classically believed to be Th1-mediated, are predominantly driven by a Th17 immune response. The aim of the work is to compare the serum levels of IL-17 in patients with SLE and RA, it is correlation with clinical presentations, laboratory findings and disease activity in both diseases. The study was carried out on 3 groups. Group I: 20 patients with SLE. Group II: 20 patients with RA. Group III: 10 of age and sex matched healthy subjects as a control group. In this study, there were no statistical significant differences between the three studied groups regarding disease duration, disease activity, laboratory investigations (except HB, WBC and platelet count). The mean serum level of IL-17 were 173.2±52.11, 82.6±48.17 and 73.07±41.05 for group I (SLE), II (RA) and III (Control) respectively, group I has values statistically higher than other groups, and group II has values statistically higher than group III. Serum IL-17 level was significantly higher in SLE patients compared to healthy group. We concluded that, Serum IL-17 concentration correlates with SLE and RA diseases activity but is significantly elevated in patients with SLE disease. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE and RA.

Published in	American Journal of Internal Medicine (Volume 4, Issue 1)
DOI	10.11648/j.ajim.20160401.12
Page(s)	5-11
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

IL-17, SLE, RA

References

[1]	Tsokos GC: Systemic lupus erythematosus. N Engl J Med 2011, 365: 2110-2121.
[2]	Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6: 1133-1141.
[3]	Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005, 6: 1123-1132.
[4]	Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology 2008; 47: 1088-92.
[5]	Plenge RM. Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep 2009; 11: 351-6.
[6]	Gonzalez A, Maradit KH, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7
[7]	Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-88.
[8]	Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
[9]	Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42: 963-970.
[10]	Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I: Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43: 2455-2463.
[11]	Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L: Gene- microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8: 500-508.
[12]	Nalbandian A, Crispin JC, Tsokos GC: Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157: 209-215.
[13]	Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW: Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385-393.
[14]	Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-785.
[15]	Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH: Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007, 27: 461-466.
[16]	Michelle Petri, Ana-Maria Orbai, Graciela S. Alarcón, Caroline Gordon, Joan T. Merrill, Paul R. Fortin, et al. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012; 64(8): 2677–2686.
[17]	Aletaha D, Neogi T, Silman AJ, et al., 2010 Rheumatoid arthritis classification criteria: an American college of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 41: 1571.
[18]	Isenberg DA, Rahman A, Allen E. Disease activity index for patients with SLE. Rheum 2005; 44: 902-6.
[19]	100. Fransen JI, van Riel PL. The Disease Activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009; 35(4): 745-57.
[20]	Dalie JV, Lwis SD. Basic haematological technique in practical hematology. 7th edition. Edinburgh, London: Churchill Livingstone; 1994. 5: 37-66.
[21]	Ritche DF, Boyle JA, Innes JM. Clinical studies with an articular index for assessment of joint tenderness in patient with rheumatoid arthritis. QJ Med 1988; 37: 393-406.
[22]	Sinico RA, Bollini B, Sabadini E, Di Toma L, Raice A. the use of laboratory tests in diagnosis and monitoring of systems lupus erythematosus. J Nephrol 2002; 15(6): 20-7.
[23]	Maneini G, Caronora AO, Herman JF. Immunochemical quantitation of antigen by single radial immune diffusion. Immunochemistry 1965; 2: 253-7.
[24]	Rose HH, Rogan B, Peass E. Differential agglutination of normal sensitized sheep erythrocyte sera of patients with rheumatoid arthritis. Pro Soc Exp Biol. 1980; 68: 1-5.
[25]	Numasaki M., J. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101 (7) (2003), pp. 2620–2627.
[26]	Fabien BV, Melissa N, Alberta H, Fabienne M and Eric FM. Clinical association of serum interleukin-17 in systemic lupus erythematosus. Arthritis research and therapy. 2013; 15: 1-9.
[27]	Chabaud M, F. Fossiez, J. L. Taupin, P. Miossec. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol, 161 (1998), pp. 409–414.
[28]	Daman L. laboratory investigation of rhematic and connective tissue disease. Sullivan Nicolaides pathology. 2014.
[29]	Jacobs R, Pawlak CR, Mikeska E, Meyer Olson D, Martin M, Heijnen J, Schedlowski M, Schmidt RE. Systemic lupus erythematosus and rheumatoid arthritis patinets differ from healthy controls in their cytokine pattern after stress exposure. Rheumatology. 2001; 40: 868-875.
[30]	Cheng F, Guo Z, Xu H, Yan D, Li Q: Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68: 604-606.
[31]	Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Su H, Pan FM, Li WX, Li LH, Chen GP, Ye DQ: Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37: 81-85.
[32]	Kotake S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999; 103: pp. 1345–1352
[33]	Metawi SA, Abbas D, Kamal MM, Ibrahim MK. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011; 30: 1201-1207.
[34]	Sarkar S, Justa S, Brucks M, Endres J, Fox DA, Zhou X, et al. Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis. Clin Exp Immunol 2014; 177: 652-661.
[35]	Kim J, Kang S, Kim J, Kwon G, Koo S. Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann Lab Med 2013; 33: 52-59.
[36]	Pavlovic V, Dimic A, Milenkovic S, Krtinic D. Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis. J Res Med Sci 2014; 19: 18-22.
[37]	Doreau A., A. Belot, J. Bastid, B. Riche, M. C. Trescol-Biemont, B. Ranchin, N. Fabien, P. Cochat, C. Pouteil-Noble, P. Trolliet, I. Durieu, J. Tebib, B. Kassai, S. Ansieau, A. Puisieux, J. F. Eliaou, N. Bonnefoy-Berard Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol., 2009; 10: pp. 778–785.

Cite This Article

Plain Text BibTeX RIS

APA Style

Eman Hassan Elsayed Hassan, Riham Fadl Moftah. (2016). Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. American Journal of Internal Medicine, 4(1), 5-11. https://doi.org/10.11648/j.ajim.20160401.12

Copy | Download

ACS Style

Eman Hassan Elsayed Hassan; Riham Fadl Moftah. Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. Am. J. Intern. Med. 2016, 4(1), 5-11. doi: 10.11648/j.ajim.20160401.12

Copy | Download

AMA Style

Eman Hassan Elsayed Hassan, Riham Fadl Moftah. Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. Am J Intern Med. 2016;4(1):5-11. doi: 10.11648/j.ajim.20160401.12

Copy | Download

@article{10.11648/j.ajim.20160401.12,
  author = {Eman Hassan Elsayed Hassan and Riham Fadl Moftah},
  title = {Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices},
  journal = {American Journal of Internal Medicine},
  volume = {4},
  number = {1},
  pages = {5-11},
  doi = {10.11648/j.ajim.20160401.12},
  url = {https://doi.org/10.11648/j.ajim.20160401.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20160401.12},
  abstract = {Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. Autoimmune diseases such as rheumatoid arthritis (RA), classically believed to be Th1-mediated, are predominantly driven by a Th17 immune response. The aim of the work is to compare the serum levels of IL-17 in patients with SLE and RA, it is correlation with clinical presentations, laboratory findings and disease activity in both diseases. The study was carried out on 3 groups. Group I: 20 patients with SLE. Group II: 20 patients with RA. Group III: 10 of age and sex matched healthy subjects as a control group. In this study, there were no statistical significant differences between the three studied groups regarding disease duration, disease activity, laboratory investigations (except HB, WBC and platelet count). The mean serum level of IL-17 were 173.2±52.11, 82.6±48.17 and 73.07±41.05 for group I (SLE), II (RA) and III (Control) respectively, group I has values statistically higher than other groups, and group II has values statistically higher than group III. Serum IL-17 level was significantly higher in SLE patients compared to healthy group. We concluded that, Serum IL-17 concentration correlates with SLE and RA diseases activity but is significantly elevated in patients with SLE disease. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE and RA.},
 year = {2016}
}

Copy | Download

TY - JOUR
T1 - Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices
AU - Eman Hassan Elsayed Hassan
AU - Riham Fadl Moftah
Y1 - 2016/02/16
PY - 2016
N1 - https://doi.org/10.11648/j.ajim.20160401.12
DO - 10.11648/j.ajim.20160401.12
T2 - American Journal of Internal Medicine
JF - American Journal of Internal Medicine
JO - American Journal of Internal Medicine
SP - 5
EP - 11
PB - Science Publishing Group
SN - 2330-4324
UR - https://doi.org/10.11648/j.ajim.20160401.12
AB - Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. Autoimmune diseases such as rheumatoid arthritis (RA), classically believed to be Th1-mediated, are predominantly driven by a Th17 immune response. The aim of the work is to compare the serum levels of IL-17 in patients with SLE and RA, it is correlation with clinical presentations, laboratory findings and disease activity in both diseases. The study was carried out on 3 groups. Group I: 20 patients with SLE. Group II: 20 patients with RA. Group III: 10 of age and sex matched healthy subjects as a control group. In this study, there were no statistical significant differences between the three studied groups regarding disease duration, disease activity, laboratory investigations (except HB, WBC and platelet count). The mean serum level of IL-17 were 173.2±52.11, 82.6±48.17 and 73.07±41.05 for group I (SLE), II (RA) and III (Control) respectively, group I has values statistically higher than other groups, and group II has values statistically higher than group III. Serum IL-17 level was significantly higher in SLE patients compared to healthy group. We concluded that, Serum IL-17 concentration correlates with SLE and RA diseases activity but is significantly elevated in patients with SLE disease. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE and RA.
VL - 4
IS - 1
ER -

Copy | Download

Author Information

Eman Hassan Elsayed Hassan

Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Riham Fadl Moftah

Clinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Eman Hassan Elsayed Hassan, Riham Fadl Moftah. (2016). Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. American Journal of Internal Medicine, 4(1), 5-11. https://doi.org/10.11648/j.ajim.20160401.12

Copy | Download

ACS Style

Eman Hassan Elsayed Hassan; Riham Fadl Moftah. Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. Am. J. Intern. Med. 2016, 4(1), 5-11. doi: 10.11648/j.ajim.20160401.12

Copy | Download

AMA Style

Eman Hassan Elsayed Hassan, Riham Fadl Moftah. Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. Am J Intern Med. 2016;4(1):5-11. doi: 10.11648/j.ajim.20160401.12

Copy | Download

@article{10.11648/j.ajim.20160401.12,
  author = {Eman Hassan Elsayed Hassan and Riham Fadl Moftah},
  title = {Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices},
  journal = {American Journal of Internal Medicine},
  volume = {4},
  number = {1},
  pages = {5-11},
  doi = {10.11648/j.ajim.20160401.12},
  url = {https://doi.org/10.11648/j.ajim.20160401.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20160401.12},
  abstract = {Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. Autoimmune diseases such as rheumatoid arthritis (RA), classically believed to be Th1-mediated, are predominantly driven by a Th17 immune response. The aim of the work is to compare the serum levels of IL-17 in patients with SLE and RA, it is correlation with clinical presentations, laboratory findings and disease activity in both diseases. The study was carried out on 3 groups. Group I: 20 patients with SLE. Group II: 20 patients with RA. Group III: 10 of age and sex matched healthy subjects as a control group. In this study, there were no statistical significant differences between the three studied groups regarding disease duration, disease activity, laboratory investigations (except HB, WBC and platelet count). The mean serum level of IL-17 were 173.2±52.11, 82.6±48.17 and 73.07±41.05 for group I (SLE), II (RA) and III (Control) respectively, group I has values statistically higher than other groups, and group II has values statistically higher than group III. Serum IL-17 level was significantly higher in SLE patients compared to healthy group. We concluded that, Serum IL-17 concentration correlates with SLE and RA diseases activity but is significantly elevated in patients with SLE disease. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE and RA.},
 year = {2016}
}

Copy | Download